Britain and America have agreed to a key commercial pact that will ensure zero duties on UK drug products going into the US market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has committed to boost funding on pharmaceuticals through the National Health Service (NHS). This pledge ensures that duties on these key goods will be held at zero for a duration of 36 months.
This deal follows recent threats to hike import taxes on patented pharmaceutical imports, with potential rates discussed up to 100%.
"This deal between the UK bolsters the international landscape for innovative medicines and introduces long-overdue fairness to U.S.–U.K. pharmaceutical trade," an announcement noted.
Trade Importance
Medicines are one of the Britain's largest export categories to the US, which is easily the biggest buyer for large companies like GSK and AstraZeneca.
Trade data reveal that in the year leading up to the third quarter, the UK exported pharmaceutical products valued at billions to the US. This figure accounted for a significant portion of all goods exports in that span.
"This agreement protects jobs, stimulates capital expenditure and facilitates the UK to emerge as a global hub for medical research," the Business and Trade Secretary remarked.
Key NHS Changes
The deal includes several key pledges from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to double total NHS spending on medicines from 0.3% of the national economy to 0.6% over the next decade.
- Rebate Cap: The amount manufacturers must refund to the NHS to control costs will be restricted at 15%. In the past, refunds exceeded twenty percent.
Broader Context
The pact follows a ongoing tension between the sector and the UK government over spending levels and regulatory access.
This friction were heightened by assertions that US customers were charged significantly more for the identical medicines than people in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been delayed or abandoned, while multi-billion-dollar funding commitments have been announced toward US facilities.
A senior figure acknowledged that the NHS needed to spend more on drugs, noting that its spending on drugs had declined as a share of its resources over the last ten years.
